⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 16, 2024

Supplementary Figure S2 from Clinical and molecular features of long-term response to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer

Rohit Thummalapalli Biagio Ricciuti Chaitanya Bandlamudi Daniel M. Muldoon Hira Rizvi Arielle Elkrief Jia Luo Joao V. Alessi Federica Pecci Giuseppe Lamberti Alessandro Di Federico Lingzhi Hong Jianjun Zhang John V. Heymach Don L. Gibbons Andrew J. Plodkowski Vignesh Ravichandran Mark T.A. Donoghue Chad Vanderbilt Marc Ladanyi Charles M. Rudin Mark G. Kris Gregory J. Riely Jamie E. Chaft Matthew D. Hellmann Natalie I. Vokes Mark M. Awad Adam J. Schoenfeld

View at Publisher

Ask AI

Bookmark

Share

Abstract

Kaplan-Meier curve of progression-free survival (PFS) among patients with long-term response (LTR) in the combined cohort.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Thummalapalli et al. (2024) studied this question.

synapsesocial.com/papers/68e586c1b6db6435875238b5 https://doi.org/10.1158/1078-0432.27033043

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S2 from Clinical and molecular features of long-term response to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer2024
2Supplementary Figure S3 from Clinical and molecular features of long-term response to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer2024
3Supplementary Figure S3 from Clinical and molecular features of long-term response to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer2024
4Supplementary Figure S4 from Clinical and molecular features of long-term response to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer2024
5Supplementary Figure S4 from Clinical and molecular features of long-term response to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer2024

More related papers

Supplementary Figure S5 from Clinical and molecular features of long-term response to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer2024
Supplementary Figure S5 from Clinical and molecular features of long-term response to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer2024
Supplementary Figure S10 from Clinical and molecular features of long-term response to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer2024